KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Cash (2016 - 2025)

Historic Change in Cash for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to -$21.8 million.

  • Emergent BioSolutions' Change in Cash fell 12552.69% to -$21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.8 million, marking a year-over-year increase of 3527.7%. This contributed to the annual value of -$6.1 million for FY2024, which is 9885.1% up from last year.
  • Emergent BioSolutions' Change in Cash amounted to -$21.8 million in Q3 2025, which was down 12552.69% from $118.2 million recorded in Q2 2025.
  • Emergent BioSolutions' Change in Cash's 5-year high stood at $401.6 million during Q4 2022, with a 5-year trough of -$344.2 million in Q2 2023.
  • Over the past 5 years, Emergent BioSolutions' median Change in Cash value was -$32.7 million (recorded in 2024), while the average stood at -$19.6 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Change in Cash plummeted by 63649.64% in 2021, and later skyrocketed by 1077500.0% in 2024.
  • Quarter analysis of 5 years shows Emergent BioSolutions' Change in Cash stood at $172.3 million in 2021, then soared by 133.08% to $401.6 million in 2022, then plummeted by 94.05% to $23.9 million in 2023, then tumbled by 312.55% to -$50.8 million in 2024, then soared by 57.09% to -$21.8 million in 2025.
  • Its Change in Cash was -$21.8 million in Q3 2025, compared to $118.2 million in Q2 2025 and $47.2 million in Q1 2025.